CoChat
Sign Up
Cited by 12Cancer Immunotherapy and BiomarkersTesticular diseases and treatmentsT-cell and B-cell Immunology

Expression of the immune checkpoint receptor TIGIT in seminoma

Open access
Hinsch, Andrea, Blessin, Niclas, Simon, Ronald, Kluth, Martina, Fischer, Kristine, Hube‑Magg, Claudia, Li, Wenchao, Makrypidi‑Fraune, Georgia +18 more·2019·Oncology Letters
DOI 10.3892/ol.2019.10428PMC PMC6607271
Open this paper in CoChat — free accountOpen PDF

Abstract

A characteristic feature of testicular seminoma is the abundance of immune cells in the tumor microenvironment, raising the possibility that immune checkpoint inhibitors may serve as a therapeutic option in these types of tumors. T cell immunoreceptor with Ig and ITIM domains (TIGIT) is an inhibitory immune checkpoint receptor in analogy to PD‑1, and drugs targeting TIGIT are currently being investigated in clinical trials. Little is known about the expression of these proteins in testicular seminomas. Therefore the present study performed immunohistochemical analysis to determine the relative abundance of TIGIT and PD‑1 in relation to the total CD3+ immune cell infiltration in a tissue microarray (TMA) constructed from 78 seminoma patients. The fraction of TIGIT+ and PD‑1+ lymphocytes was highly variable in individual cancers and ranged from 2.3 to 69.4% (mean: 32.2±14.7%) for TIGIT and from 0.8 to 56.5% (mean: 21.6±13.2%) for PD‑1. The same high degree of variability was also identified for the ratio of PD‑1 to TIGIT positive cells, which varied from a dominance of TIGIT (PD‑1: TIGIT ratio=0.02) in 74% of patients, to a predominance of PD‑1 (PD‑1: TIGIT ratio=12.5) in 23% of patients. In summary, the immune checkpoint receptors TIGIT and PD‑1 are abundantly expressed in human seminomas. Once available, anti‑TIGIT antibodies, possibly in combination with anti‑PD‑1 drugs, may be a reasonable therapeutic strategy for this type of cancer.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3892/ol.2019.10428

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In seminoma samples, several immune checkpoint receptors are overexpressed in the cancerous cells.

    “A recent immunohistochemical analysis of seminoma samples revealed the overexpression of several immune checkpoint receptors in the cancerous cells.”

    From The Immune Landscape and Immunotherapeutic Strategies in Platinum-Refractory Testicular Germ Cell Tumors (2024) · cites this paper as [57]

    The Results (page unavailable) report TIGIT and PD-1 staining in immune cells within all 78 seminomas, not overexpression in the cancerous cells. The Introduction likewise says the study examined these receptors on lymphocytes. The claim assigns the finding to the wrong cell type. (LLM, conf=0.88)

    Checked by a reasoning model — may be wrong.

    Experimental — accuracy not yet measured

  • TIGIT is significantly overexpressed in seminoma samples.

    “Notably, TIGIT (T-cell immunoreceptor with Ig and ITIM domains) was found to be significantly overexpressed [57].”

    From The Immune Landscape and Immunotherapeutic Strategies in Platinum-Refractory Testicular Germ Cell Tumors (2024) · cites this paper as [57]

    The Results report TIGIT-positive lymphocytes in all 78 seminomas, and the Discussion describes TIGIT expression in their tumor-infiltrating T cells. The paper reports variable abundance, but does not establish statistically significant overexpression against a specified comparator. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 35

  1. [1]Hayes-Lattin B Nichols CR Testicular cancer: A prototypic tumor of young adults Semin Oncol 36 432 438 2009 10.1053/j.seminoncol.2009.07.006 19835738 PMC2796329 · DOI
  2. [2]Krege S Beyer J Souchon R Albers P Albrecht W Algaba F Bamberg M Bodrogi I Bokemeyer C Cavallin-Ståhl E European consensus conference on diagnosis and treatment of germ cell cancer: A report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part I Eur Urol 53 478 496 2008 10.1016/j.eururo.2007.12.024 18191324 · DOI
  3. [3]Hanna N Einhorn LH Testicular cancer: A reflection on 50 years of discovery J Clin Oncol 32 3085 3092 2014 10.1200/JCO.2014.56.0896 25024068 · DOI
  4. [4]Adra N Einhorn LH Salvage therapy for relapsed testicular cancer Oncotarget 8 69200 69201 2017 10.18632/oncotarget.20872 29050196 PMC5642471 · DOI
  5. [5]Oing C Alsdorf WH von Amsberg G Oechsle K Bokemeyer C Platinum-refractory germ cell tumors: An update on current treatment options and developments World J Urol 35 1167 1175 2017 10.1007/s00345-016-1898-z 27449639 · DOI
  6. [7]Adra N Einhorn LH Althouse SK Ammakkanavar NR Musapatika D Albany C Vaughn D Hanna NH Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: A hoosier cancer research network study GU14-206 Ann Oncol 29 209 214 2018 10.1093/annonc/mdx680 29045540 · DOI · Paper page
  7. [8]Ansell SM Lesokhin AM Borrello I Halwani A Scott EC Gutierrez M Schuster SJ Millenson MM Cattry D Freeman GJ PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma N Engl J Med 372 311 319 2015 10.1056/NEJMoa1411087 25482239 PMC4348009 · DOI
  8. [9]Wolchok JD Kluger H Callahan MK Postow MA Rizvi NA Lesokhin AM Segal NH Ariyan CE Gordon RA Reed K Nivolumab plus ipilimumab in advanced melanoma N Engl J Med 369 122 133 2013 10.1056/NEJMoa1302369 23724867 PMC5698004 · DOI · Paper page
  9. [10]Alsaab HO Sau S Alzhrani R Tatiparti K Bhise K Kashaw SK Iyer AK PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: Mechanism, combinations, and clinical outcome Front Pharmacol 8 561 2017 10.3389/fphar.2017.00561 28878676 PMC5572324 · DOI
  10. [13]Liu XG Hou M Liu Y TIGIT, a novel therapeutic target for tumor immunotherapy Immunol Invest 46 172 182 2017 10.1080/08820139.2016.1237524 27819527 · DOI
  11. [14]Manieri NA Chiang EY Grogan JL TIGIT: A key inhibitor of the cancer immunity cycle Trends Immunol 38 20 28 2017 10.1016/j.it.2016.10.002 27793572 · DOI
  12. [15]Dougall WC Kurtulus S Smyth MJ Anderson AC TIGIT and CD96: New checkpoint receptor targets for cancer immunotherapy Immunol Rev 276 112 120 2017 10.1111/imr.12518 28258695 · DOI
  13. [16]Johnston RJ Comps-Agrar L Hackney J Yu X Huseni M Yang Y Park S Javinal V Chiu H Irving B The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function Cancer Cell 26 923 937 2014 10.1016/j.ccell.2014.10.018 25465800 · DOI
  14. [17]Chauvin JM Pagliano O Fourcade J Sun Z Wang H Sander C Kirkwood JM Chen TH Maurer M Korman AJ Zarour HM TIGIT and PD-1 impair tumor antigen-specific CD8+ T cells in melanoma patients J Clin Invest 125 2046 2058 2015 10.1172/JCI80445 25866972 PMC4463210 · DOI
  15. [18]Kurtulus S Sakuishi K Ngiow SF Joller N Tan DJ Teng MW Smyth MJ Kuchroo VK Anderson AC TIGIT predominantly regulates the immune response via regulatory T cells J Clin Invest 125 4053 4062 2015 10.1172/JCI81187 26413872 PMC4639980 · DOI
  16. [19]Blessin NC Simon R Kluth M Fischer K Hube-Magg C Li W Makrypidi-Fraune G Wellge B Mandelkow T Debatin NF Patterns of TIGIT expression in normal lymphatic tissue, inflammation, and cancer Dis Markers 2019 5160565 2019 10.1155/2019/5160565 30733837 PMC6348838 · DOI
  17. [20]Garber K Industry ‘road tests’ new wave of immune checkpoints Nat Biotechnol 35 487 488 2017 10.1038/nbt0617-487 28591107 · DOI
  18. [21]Kong Y Zhu L Schell TD Zhang J Claxton DF Ehmann WC Rybka WB George MR Zeng H Zheng H T-cell immunoglobulin and ITIM domain (TIGIT) associates with CD8+ T-Cell exhaustion and poor clinical outcome in AML patients Clin Cancer Res 22 3057 3066 2016 10.1158/1078-0432.CCR-15-2626 26763253 · DOI
  19. [22]Kononen J Bubendorf L Kallioniemi A Bärlund M Schraml P Leighton S Torhorst J Mihatsch MJ Sauter G Kallioniemi OP Tissue microarrays for high-throughput molecular profiling of tumor specimens Nat Med 4 844 847 1998 10.1038/nm0798-844 9662379 · DOI
  20. [24]Josefsson SE Huse K Kolstad A Beiske K Pende D Steen CB Inderberg EM Lingjærde OC Østenstad B Smeland EB T cells expressing checkpoint receptor TIGIT are enriched in follicular lymphoma tumors and characterized by reversible suppression of T-cell receptor signaling Clin Cancer Res 24 870 881 2018 10.1158/1078-0432.CCR-17-2337 29217528 PMC5815910 · DOI
  21. [25]Luo Q Deng Z Xu C Zeng L Ye J Li X Guo Y Huang Z Li J Elevated expression of immunoreceptor tyrosine-based inhibitory motif (TIGIT) on T lymphocytes is correlated with disease activity in rheumatoid arthritis Med Sci Monit 23 1232 1241 2017 10.12659/MSM.902454 28282368 PMC5358849 · DOI
  22. [26]Yu X Harden K Gonzalez LC Francesco M Chiang E Irving B Tom I Ivelja S Refino CJ Clark H The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells Nat Immunol 10 48 57 2009 10.1038/ni.1674 19011627 · DOI
  23. [28]Topalian SL Hodi FS Brahmer JR Gettinger SN Smith DC McDermott DF Powderly JD Carvajal RD Sosman JA Atkins MB Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med 366 2443 2454 2012 10.1056/NEJMoa1200690 22658127 PMC3544539 · DOI · Paper page
  24. [29]Farkona S Diamandis EP Blasutig IM Cancer immunotherapy: The beginning of the end of cancer? BMC Med 14 73 2016 10.1186/s12916-016-0623-5 27151159 PMC4858828 · DOI
  25. [30]Siska PJ Johnpulle RAN Zhou A Bordeaux J Kim JY Dabbas B Dakappagari N Rathmell JC Rathmell WK Morgans AK Deep exploration of the immune infiltrate and outcome prediction in testicular cancer by quantitative multiplexed immunohistochemistry and gene expression profiling Oncoimmunology 6 e1305535 2017 10.1080/2162402X.2017.1305535 28507813 PMC5414873 · DOI · Paper page
  26. [31]Mandelkow T Blessin NC Lueerss E Pott L Simon R Li W Wellege B Debatin NF Hoflmayer D Izbicki JR Immune exclusion is frequent in small cell carcinoma of the bladder Disease Markers Article ID 2532518 2019 10.1155/2019/2532518 31191745 PMC6525886 · DOI
  27. [32]Garcia-Martinez E Gil GL Benito AC González-Billalabeitia E Conesa MA García García T García-Garre E Vicente V Ayala de la Peña F Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer Breast Cancer Res 16 488 2014 10.1186/s13058-014-0488-5 25432519 PMC4303200 · DOI
  28. [33]Galon J Costes A Sanchez-Cabo F Kirilovsky A Mlecnik B Lagorce-Pagès C Tosolini M Camus M Berger A Wind P Type, density, and location of immune cells within human colorectal tumors predict clinical outcome Science 313 1960 1964 2006 10.1126/science.1129139 17008531 · DOI · Paper page
  29. [34]Fabre E Jira H Izard V Ferlicot S Hammoudi Y Theodore C Di Palma M Benoit G Droupy S ‘Burned-out’ primary testicular cancer BJU Int 94 74 78 2004 10.1111/j.1464-410X.2004.04904.x 15217435 · DOI
  30. [35]Hanna NH Einhorn LH Testicular cancer-discoveries and updates N Engl J Med 371 2005 2016 2014 10.1056/NEJMra1407550 25409373 · DOI
  31. [37]Abouassaly R Fossa SD Giwercman A Kollmannsberger C Motzer RJ Schmoll HJ Sternberg CN Sequelae of treatment in long-term survivors of testis cancer Eur Urol 60 516 526 2011 10.1016/j.eururo.2011.05.055 21684072 · DOI
  32. [38]Wethal T Kjekshus J Røislien J Ueland T Andreassen AK Wergeland R Aukrust P Fosså SD Treatment-related differences in cardiovascular risk factors in long-term survivors of testicular cancer J Cancer Surviv 1 8 16 2007 10.1007/s11764-007-0012-3 18648940 · DOI
  33. [39]Ribas A Puzanov I Dummer R Schadendorf D Hamid O Robert C Hodi FS Schachter J Pavlick AC Lewis KD Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): A randomised, controlled, phase 2 trial Lancet Oncol 16 908 918 2015 10.1016/S1470-2045(15)00083-2 26115796 PMC9004487 · DOI
  34. [40]Brahmer J Reckamp KL Baas P Crinò L Eberhardt WE Poddubskaya E Antonia S Pluzanski A Vokes EE Holgado E Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer N Engl J Med 373 123 135 2015 10.1056/NEJMoa1504627 26028407 PMC4681400 · DOI · Paper page
  35. [41]Li W Blessin NC Simon R Kluth M Fischer K Hube-Magg C Makrypidi-Fraune G Wellge B Mandelkow T Debatin NF Expression of the immune checkpoint receptor TIGIT in Hodgkin's lymphoma BMC Cancer 18 1209 2018 10.1186/s12885-018-5111-1 30514251 PMC6280445 · DOI

Cited by

Sorted by citations

Authors
Hinsch, A., Blessin, N., Simon, R., Kluth, M., Fischer, K., Hube‑Magg, C., Li, W., Makrypidi‑Fraune, G., Wellge, B., Mandelkow, T., Debatin, N., H�flmayer, D., Lennartz, M., Sauter, G., Izbicki, J., Minner, S., B�scheck, F., Uhlig, R., Dum, D., Krech, T., Luebke, A., Wittmer, C., Jacobsen, F., Burandt, E., Steurer, S., & Wilczak, W.
Affiliations
  • University Medical Center Hamburg-Eppendorf (DE)
  • Hochschule für bildende Künste (DE)
  • Department of Pathology, University Medical Center Hamburg‑Eppendorf, D‑20246 Hamburg, Germany
Corresponding author
Simon, Ronald
ORCID
Venue
Oncology Letters
Publisher
Spandidos Publications
Published
2019-05-31
Volume
18
Issue
2
Pages
1497-1502
ISSN
  • 1792-1074 (ISSN-L)
  • 1792-1082
DOI
10.3892/ol.2019.10428
PMC
PMC6607271
OpenAlex
W2947677762
Cited by
12
References
5
Citations by year
2025: 2 · 2024: 2 · 2023: 2 · 2021: 2 · 2020: 3 · 2019: 1
FWCI
0.63
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Oncology Letters (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Surgery › Testicular diseases and treatments
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
TIGIT, PD-1, seminoma, immune checkpoint receptors, tumor microenvironment, CD3+ T cell infiltration, immune checkpoint inhibitors, anti-PD-1 combination therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review